Ultragenyx Pharmaceutical (RARE) Equity Income (2019 - 2025)
Ultragenyx Pharmaceutical (RARE) reported Equity Income of $678000.0 for Q3 2025, little changed year-over-year from $678000.0 in Q3 2024, and up 7633.33% quarter-over-quarter from -$9000.0 in Q2 2025.
Ultragenyx Pharmaceutical (RARE) Equity Income (2019 - 2025) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 7 years of Equity Income data on file, last reported at $678000.0 in Q3 2025.
- Equity Income for Q3 2025 came in at $678000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.0 million (down 144.62% YoY), and the FY2024 annual result was -$1.1 million, down 380.86% from the prior year.
- Equity Income grew to $678000.0 in Q3 2025 per RARE's latest filing, from -$9000.0 in the prior quarter.
- Over five years, Equity Income peaked at $25.7 million in Q3 2021 and troughed at -$31.0 million in Q2 2021.
- A 5-year average of -$3.2 million and a median of -$334000.0 in 2023 frame the typical range for Equity Income.
- On a YoY basis, Equity Income climbed as much as 1221.56% in 2024 and fell as far as 1629.12% in 2024.
- A 5-year view of Equity Income shows it stood at -$16.1 million in 2021, then jumped by 111.43% to $1.8 million in 2022, then advanced by 2.66% to $1.9 million in 2023, then slumped by 181.95% to -$1.5 million in 2024, then soared by 143.8% to $678000.0 in 2025.
- Business Quant data shows RARE's Equity Income at $678000.0 in Q3 2025, -$9000.0 in Q2 2025, and -$157000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.45 Bn | 2.05 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 678,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | -157,000.00 |
| Dec 31, 2024 | -1.55 Mn |
| Sep 30, 2024 | 678,000.00 |
| Jun 30, 2024 | -3.99 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | -334,000.00 |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | -1.63 Mn |
| Jun 30, 2022 | -10.18 Mn |
| Mar 31, 2022 | -9.33 Mn |
| Dec 31, 2021 | -16.10 Mn |
| Sep 30, 2021 | 25.70 Mn |
| Jun 30, 2021 | -31.05 Mn |
| Mar 31, 2021 | -20.62 Mn |
| Dec 31, 2020 | 79.06 Mn |